WallStSmart

Alcon AG (ALC)vsAnbio Biotechnology Class A Ordinary Shares (NNNN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Alcon AG generates 125507% more annual revenue ($10.86B vs $8.65M). NNNN leads profitability with a 74.1% profit margin vs 5.9%. NNNN trades at a lower P/E of 43.1x. NNNN earns a higher WallStSmart Score of 51/100 (C-).

ALC

Buy

51

out of 100

Grade: C-

Growth: 4.7Profit: 4.5Value: 3.3Quality: 6.8
Piotroski: 3/9

NNNN

Buy

51

out of 100

Grade: C-

Growth: 5.3Profit: 9.0Value: 4.7Quality: 6.5
Piotroski: 4/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ALCSignificantly Overvalued (-22.0%)

Margin of Safety

-22.0%

Fair Value

$65.08

Current Price

$66.03

$0.95 premium

UndervaluedFair: $65.08Overvalued

Intrinsic value data unavailable for NNNN.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ALC2 strengths · Avg: 9.5/10
Price/BookValuation
1.5x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

NNNN4 strengths · Avg: 9.8/10
Profit MarginProfitability
74.1%10/10

Keeps 74 of every $100 in revenue as profit

Operating MarginProfitability
59.1%10/10

Strong operational efficiency at 59.1%

Revenue GrowthGrowth
73.9%10/10

Revenue surging 73.9% year-over-year

Return on EquityProfitability
23.8%9/10

Every $100 of equity generates 24 in profit

Areas to Watch

ALC4 concerns · Avg: 2.8/10
Return on EquityProfitability
3.8%3/10

ROE of 3.8% — below average capital efficiency

Profit MarginProfitability
5.9%3/10

5.9% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

P/E RatioValuation
53.8x2/10

Premium valuation, high expectations priced in

NNNN4 concerns · Avg: 3.3/10
Price/BookValuation
9.2x4/10

Trading at 9.2x book value

EPS GrowthGrowth
2.8%4/10

2.8% earnings growth

Market CapQuality
$283.98M3/10

Smaller company, higher risk/reward

P/E RatioValuation
43.1x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : ALC

The strongest argument for ALC centers on Price/Book, Debt/Equity. PEG of 1.27 suggests the stock is reasonably priced for its growth.

Bull Case : NNNN

The strongest argument for NNNN centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 74.1% and operating margin at 59.1%. Revenue growth of 73.9% demonstrates continued momentum.

Bear Case : ALC

The primary concerns for ALC are Return on Equity, Profit Margin, Piotroski F-Score. A P/E of 53.8x leaves little room for execution misses.

Bear Case : NNNN

The primary concerns for NNNN are Price/Book, EPS Growth, Market Cap. A P/E of 43.1x leaves little room for execution misses.

Key Dynamics to Monitor

ALC profiles as a value stock while NNNN is a growth play — different risk/reward profiles.

NNNN is growing revenue faster at 73.9% — sustainability is the question.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ALC scores higher overall (51/100 vs 51/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alcon AG

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Alcon, Inc., an eye care company, researches, develops, manufactures, distributes and sells eye care products for eye care professionals and their patients around the world. The company is headquartered in Geneva, Switzerland.

Visit Website →

Anbio Biotechnology Class A Ordinary Shares

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. The company is headquartered in Frankfurt am Main, Germany.

Want to dig deeper into these stocks?